key: cord-1026408-1getk5oq authors: Talasaz, Azita H.; Sadeghipour, Parham; Aghakouchakzadeh, Maryam; Dreyfus, Isaac; Kakavand, Hessam; Ariannejad, Hamid; Gupta, Aakriti; Madhavan, Mahesh V.; Van Tassell, Benjamin W.; Jimenez, David; Monreal, Manuel; Vaduganathan, Muthiah; Fanikos, John; Dixon, Dave L.; Piazza, Gregory; Parikh, Sahil A.; Bhatt, Deepak L.; Lip, Gregory Y.H.; Stone, Gregg W.; Krumholz, Harlan M.; Libby, Peter; Goldhaber, Samuel Z.; Bikdeli, Behnood title: Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review date: 2021-10-19 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2021.08.021 sha: 76193b31c7f360d9adca238310cdfce6dab53979 doc_id: 1026408 cord_uid: 1getk5oq Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. S evere acute respiratory syndromecoronavirus-2 (SARS-CoV-2) cellular entry is mediated by attachment to angiotensin-converting enzyme 2 (ACE2). Lipid rafts are plasma membrane microdomains, mainly composed of cholesterol, glycosphingolipids, and phospholipids, capable of changing their composition in response to stimuli that may play a critical role in this process (1) . SARS-CoV-2 can trigger an Figure 2 illustrates the potential pathways through which lipid-modulating drugs that have ongoing RCTs may affect outcomes in COVID-19. These agents include statins, omega-3 fatty acids, fibrates, niacin, and dalcetrapib. Statins inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (20) and the production of isoprenoid intermediates that are critical for viral entry, immune signaling, and the inflammatory cascade (21) . These agents also induce transcription factors such as Krüppel-like factor-2, limiting inflammation and prothrombotic functions of activated endothelial cells (22) . Statins exert antioxidant and antiapoptotic effects, potentiate the production of nitric oxide (3, 23) , and up-regulate transforming growth factor beta receptor III, thereby reducing collagen deposition and pulmonary fibrosis (24) . Data in observational studies, RCTs, and metaanalyses in patients with sepsis are controversial. Two RCTs showed no improvement in acute respiratory distress syndrome (ARDS) versus placebo (25, 26) . However, some studies suggest a benefit associated with statin use (27) . Dalcetrapib Lipid-Modifying Therapy RCTs in COVID-19 Lipid-Modifying Therapy RCTs in COVID-19 Omega-3 fatty acid preparations are being assessed among non-intensive care unit (ICU) inpatients, and outpatients. *See full list of inclusion/exclusion criteria in the original trial records. † Enrollment setting includes hospitalized non-ICU patients and outpatient settings. BMI ¼ body mass index; CVD ¼ cardiovascular disease; qSOFA ¼ quick Sequential Organ Failure Assessment; TNF ¼ tumor necrosis factor; other abbreviations as in Figure 3 . Full study names are provided in the text. Lipid-Modifying Therapy RCTs in COVID-19 Figure 2 . The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain COVID-19: immunopathology and its implications for therapy COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-ofthe-art review COVID-19 is, in the end, an endothelial disease Pleiotropic effects of statins on the cardiovascular system Low HDL and high triglycerides predict COVID-19 severity Targeting lipid rafts-a potential therapy for COVID-19 MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV Inhibition of NF-kB-mediated inflammation in severe acute respiratory syndrome coronavirusinfected mice increases survival Statins differ in their ability to block NF-kappaB activation in human blood monocytes Statins may decrease the fatality rate of Middle East respiratory syndrome infection Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION/INSPIRATION-S studies Atorvastatin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial Stimulating the resolution of inflammation through omega-3 polyunsaturated fatty acids in COVID-19: rationale for the COVID-Omega-F trial Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE) Letter to the editor: study summary-randomized control trial of omega-3 fatty acid supplementation for the treatment of COVID-19 related olfactory dysfunction Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial Effects of icosapent ethyl on inflammatory biomarkers in individuals with COVID-19-VASCEPA COVID-19 Car-dioLink-9. Paper presented at: National Lipid Association Virtual Scientific Sessions Pharmacology of cholesterol and lipoprotein metabolism Mechanisms of action and efficacy of statins against influenza KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation Statins in the intensive care unit Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-b receptor III expression Simvastatin in the acute respiratory distress syndrome Rosuvastatin for sepsis-associated acute respiratory distress syndrome Statins: a viable candidate for host-directed therapy against infectious diseases Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19 The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19 The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models. bioRxiv Nicotinamide riboside-the current state of research and therapeutic uses COVID-19-associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches Effects of torcetrapib in patients at high risk for coronary events PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Atorvastatin vs placebo in patients with COVID-19 admitted to the ICU: the INSPIRATION-S Trial. American College of Cardiology Scientific Sessions Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC State-ofthe-Art Review Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective Dexamethasone in hospitalized patients with Covid-19 Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial Tocilizumab for severe COVID-19: a systematic review and meta-analysis Efficacy of tocilizumab in patients hospitalized with Covid-19 Beneficial effect of statins in COVID-19-related outcomes-brief report: a national population-based cohort study Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? Physician variation in the de-adoption of ineffective statin and fibrate therapy Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19 Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy Effects of extendedrelease niacin with laropiprant in high-risk patients Effects of dalcetrapib in patients with a recent acute coronary syndrome Effects of anacetrapib in patients with atherosclerotic vascular disease Reducing the cardiovascular disease burden: justified means for getting to the end N-of-1 trial of a statin, placebo, or no treatment to assess side effects Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, doubleblind, double-mimic, randomized clinical trial Cardiovascular complications of COVID-19: pharmacotherapy perspective Safety and efficacy of statin therapy High-dose statin therapy Lipid-Modifying Therapy RCTs in COVID-19 risk of intracerebral hemorrhage: a meta-analysis Adverse effects of statin therapy: perception vs. the evidence-focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized controlled trial Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated metaanalysis of randomized controlled trials Nicotinamide: an update and review of safety & differences from niacin KEY WORDS COVID-19, fibrate, lipidmodulating agent, niacin